Fig. 2: Clinical outcomes of regorafenib–nivolumab.
From: Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial
a, Waterfall plot showing the change in the sum of target lesion diameters. b, Spider plot showing changes in the sum of target lesion diameters throughout treatment. Red box represents early progressors. Blue box represents long-term responders. c, PFS and OS of the study population.
